-
We stay positive on Frencken (SGX:E28) over the robust global semiconductor outlook. 1Q26 revenue and core earnings were within expectations, with momentum expected to accelerate into 2Q26 and 2H26. We expect growth to be led by more orders, on the back of better visibility on customers’ projected orders.
1Q26 revenue in line.
- - Read this at SGinvestors.io -
-
The mechatronics division’s decline was led by the semiconductor segment (-7% y-o-y to S$99m) as a result of lower sales to Europe, as orders moderated from its peak level in 2025 for an advanced module in extreme ultraviolet (EUV) systems. Revenue from the medical segment grew 5% y-o-y to S$35m from more customer orders in Europe. The analytical life sciences segment’s revenue fell 21% y-o-y to S$36m on soft customer demand in Europe. The industrial automation segment’s revenue was stable at S$8m, as its key data storage customer upgraded and maintained its assembly and test lines. The APS division’s revenue growth was due to automotive (12% y-o-y, S$16m), offset by slower sales in the consumer and industrial electronics (-5.2% y-o-y, S$4m) segments.
- - Read this at SGinvestors.io -
Expect a stronger 2H26.
- Read more at SGinvestors.io.
Above is an excerpt from a report by RHB Securities Research.
Clients of RHB may be the first to access the full PDF report @ https://www.rhbtradesmart.com/.
Alfie Yeo RHB Securities Research | https://www.rhbgroup.com/ 2026-05-22
Previous report by RHB:
2026-05-13 Frencken - Expecting Order Acceleration In 2H26.
Price targets by 4 other brokers at Frencken Target Prices.
Listing of research reports at Frencken Analyst Reports.
Relevant links:
Frencken Share Price History,
Frencken Announcements,
Frencken Dividend Payout Dates & Corporate Actions,
Frencken News
